Instead of just searching for top performers while combing through fund management filings, Filings Analysis narrows the screen to top performing healthcare managers - those shown to have made the right picks in that sector over time even if position sizing or choices outside of healthcare fared poorly. Four managers made the cut: Palo Alto Investors, Perceptive Advisors, Perkins Capital Management, and Michael Murphy.
New holdings for Palo Alto were Ariad ARIA and NPS Pharmaceuticals NPSP, while the firm added to holdings in Clovis (CLVS +2.4%) and Hyperion Therapeutics (HPTX -2.1%).
Perceptive initiated a number of new positions, but none were large. The top two: Macrogenics (MGNX +1.3%) and Abbvie (ABBV -0.5%).
Perkins also added a number of new names: Conmed (CNMD +0.8%), Combimatrix (CMBX), Iridex (IRIX -2.8%), and Cardiome Pharm (CRME +0.4%).
24/7's Lee Jackson pinpoints eight small-cap biotech ideas, whose stocks all trade near $5 but with big upside potential; each company has promising clinical trials and in some cases FDA-approved products already on the market or soon to arrive.
Galena Biopharma (GALE) "may be the home run that biotech investors are looking for," and the stock may be an acquisition target; Novavax (NVAX) has six vaccine candidates undergoing clinical trials and a seventh being readied for a Phase I study later this year.
The FDA accepts NPS Pharmaceuticals' (NPSP) sNDA for Gattex.
The company wants STEPS 2 data included on the SBS treatment's label.
"The data ... we're proposing to include ... show that patients on treatment beyond one year continue to achieve clinically meaningful reductions in parenteral support requirements, with some achieving complete independence," NPS notes. (PR)
Brean's Jonathan Aschoff becomes the second analyst to come to NPS Pharmaceuticals' (NPSP -15.5%) defense after the shares plummeted Wednesday morning following Gattex guidance that perhaps wasn't as ebullient as the Street was hoping for.
"NPS delivered an above-expectation quarter again," Aschoff notes, adding that the company's guidance for patients on therapy by year-end "suggests a similar rate of new patient adds over Q4 as over Q3."